WO2023118961 - ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF
National phase entry:
Publication Number
WO/2023/118961
Publication Date
29.06.2023
International Application No.
PCT/IB2022/000772
International Filing Date
20.12.2022
Title **
[English]
ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF
[French]
CONJUGUÉS ANTICORPS-MÉDICAMENT COMPRENANT DES TOXINES AVEC DES GROUPES POLAIRES ET LEURS UTILISATIONS
Applicants **
INTOCELL, INC.
101, Sinildong-ro
Daedeok-gu
Daejeon
34324, KR
Inventors
PARK, Taekyo
Intocell, Inc.
101, Sinildong-ro
Daedeok-gu
Daejeon
34324, KR
REW, Yosup
Intocell, Inc.
101, Sinildong-ro
Daedeok-gu
Daejeon
34324, KR
KIM, Sunyoung
Intocell, Inc.
101, Sinildong-ro
Daedeok-gu
Daejeon
34324, KR
JUNG, Doohwan
Intocell, Inc.
101, Sinildong-ro
Daedeok-gu
Daejeon
34324, KR
SEO, Donghoon
Intocell, Inc.
101, Sinildong-ro
Daedeok-gu
Daejeon
34324, KR
LEE, Sangkwang
Intocell, Inc.
101, Sinildong-ro
Daedeok-gu
Daejeon
34324, KR
HA, Jihyeon
Intocell, Inc.
101, Sinildong-ro
Daedeok-gu
Daejeon
34324, KR
CHOI, Jihye
Intocell, Inc.
101, Sinildong-ro
Daedeok-gu
Daejeon
34324, KR
JEON, Cheolmin
Intocell, Inc.
101, Sinildong-ro
Daedeok-gu
Daejeon
34324, KR
JEONG, Myeonghwa
Intocell, Inc.
101, Sinildong-ro
Daedeok-gu
Daejeon
34324, KR
KIM, Hyewon
Intocell, Inc.
101, Sinildong-ro
Daedeok-gu
Daejeon
34324, KR
YANG, Eun, Hye
Intocell, Inc.
101, Sinildong-ro
Daedeok-gu
Daejeon
34324, KR
KIM, Ya, Gob
Intocell, Inc.
101, Sinildong-ro
Daedeok-gu
Daejeon
34324, KR
LEE, Chohee
Intocell, Inc.
101, Sinildong-ro
Daedeok-gu
Daejeon
34324, KR
LEE, Hyang, Sook
Intocell, Inc.
101, Sinildong-ro
Daedeok-gu
Daejeon
34324, KR
SEO, Beomseok
Intocell, Inc.
101, Sinildong-ro
Daedeok-gu
Daejeon
34324, KR
SONG, Jina
Intocell, Inc.
101, Sinildong-ro
Daedeok-gu
Daejeon
34324, KR
KIM, Sena
Intocell, Inc.
101, Sinildong-ro
Daedeok-gu
Daejeon
34324, KR
YOO, Jae, Do
Intocell, Inc.
101, Sinildong-ro
Daedeok-gu
Daejeon
34324, KR
Priority Data
63/292,101
21.12.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
MOIP
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 10945 | |
| EPO | Filing, Examination | 201345 | |
| Japan | Filing | 588 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 58460 |
Total: 271912 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure is directed toward drugs and toxins functionalized by at least one saccharide, sulfate or sulfonate; drug conjugates comprising said drugs or toxins and a cleavable linker; and targeted conjugates comprising said drugs or toxins, cleavable linkers, and targeting moieties. The present disclosure also relates to methods of treating cancers, auto- immune diseases, and inflammatory diseases using the compounds and conjugates of the disclosure.[French]
La présente invention concerne des médicaments et des toxines fonctionnalisés par au moins un saccharide, un sulfate ou un sulfonate; des conjugués médicamenteux comprenant lesdits médicaments ou toxines et un lieur clivable; et des conjugués ciblés comprenant lesdits médicaments ou toxines, des lieurs clivables et des fractions de ciblage. La présente invention concerne également des méthodes de traitement de cancers, de maladies auto-immunes et de maladies inflammatoires à l'aide des composés et des conjugués de l'invention.